These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 22812555)

  • 41. Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis.
    Ma Z; Liu X; Xu X; Jiang J; Zhou J; Wang J; Chen D; Luo S
    Medicine (Baltimore); 2017 Jun; 96(25):e7145. PubMed ID: 28640088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monitoring patients with ankylosing spondylitis on anti-TNF monotherapy: too much too often?
    Gunasekera W; Creamer P; Creamer K; Sengupta R
    Scand J Rheumatol; 2017 Jul; 46(4):330-331. PubMed ID: 27733090
    [No Abstract]   [Full Text] [Related]  

  • 43. Socioeconomic consequences of ankylosing spondylitis.
    Boonen A
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S23-6. PubMed ID: 12463442
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research.
    Kim HW; Kwon SR; Jung KH; Kim SK; Baek HJ; Seo MR; Bang SY; Lee HS; Suh CH; Jung JY; Son CN; Shim SC; Lee SH; Lee SG; Lee YA; Lee EY; Kim TH; Kim YG;
    PLoS One; 2016; 11(4):e0153816. PubMed ID: 27101309
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A systematic literature review of the economic impact of ankylosing spondylitis.
    Palla I; Trieste L; Tani C; Talarico R; Cortesi PA; Mosca M; Turchetti G
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S136-41. PubMed ID: 23072824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.
    Borse RH; Brown C; Muszbek N; Chaudhary MA; Kachroo S
    Rheumatol Ther; 2017 Dec; 4(2):427-443. PubMed ID: 28956301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Disease relapse and treatment strategies after discontinuation of anti-tumor necrosis factor-alpha therapy in patients with ankylosing spondylitis].
    Zhang SL; Huang F
    Zhonghua Nei Ke Za Zhi; 2011 Nov; 50(11):905-7. PubMed ID: 22333119
    [No Abstract]   [Full Text] [Related]  

  • 48. Economic considerations of the treatment of ankylosing spondylitis.
    Reveille JD; Ximenes A; Ward MM
    Am J Med Sci; 2012 May; 343(5):371-4. PubMed ID: 22543541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ankylosing spondylitis: what is the cost to society, and can it be reduced?
    Boonen A; Severens JL
    Best Pract Res Clin Rheumatol; 2002 Sep; 16(4):691-705. PubMed ID: 12406435
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Recommendations for starting anti TNF-alpha in patients with ankylosing spondylitis].
    Olivieri I; Salvarani C; Cantini F; Punzi L; Matucci Cerinic M
    Reumatismo; 2003; 55(4):220-3. PubMed ID: 14872220
    [No Abstract]   [Full Text] [Related]  

  • 51. Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study.
    Tran-Duy A; Boonen A; van de Laar MA; Severens JL
    Cost Eff Resour Alloc; 2015; 13():18. PubMed ID: 26451133
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment patterns, complications, and direct medical costs associated with ankylosing spondylitis in Chinese urban patients: a retrospective claims dataset analysis.
    Li J; Liu Q; Chen Y; Gao S; Zhang J; Yang Y; Chen W
    J Med Econ; 2017 Jan; 20(1):91-97. PubMed ID: 27552493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis.
    Malinowski KP; Kawalec P
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):285-300. PubMed ID: 25579502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Tumor necrosis factor blocking agents: a review. Part II: safety and recommendations].
    Rodríguez Moreno C; López Vázquez P; Durán Parrondo C; Tato Herrero F; Lado Lado F; Velasco González M
    An Med Interna; 2006 Feb; 23(2):86-92. PubMed ID: 16566659
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transcriptome analysis of ankylosing spondylitis patients before and after TNF-α inhibitor therapy reveals the pathways affected.
    Wang XB; Ellis JJ; Pennisi DJ; Song X; Batra J; Hollis K; Bradbury LA; Li Z; Kenna TJ; Brown MA
    Genes Immun; 2017 Sep; 18(3):184-190. PubMed ID: 28835680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost effective analysis of ribosome-component immune modulation.
    Fiocchi A; Olivieri D; Marcassa S; Zava D; Robberto E
    Allergy Asthma Proc; 2009; 30 Suppl 1():S37-9. PubMed ID: 19679004
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost of disease-modifying therapies for multiple sclerosis.
    Brown MG
    Neurology; 2015 May; 84(21):e181-5. PubMed ID: 26009567
    [No Abstract]   [Full Text] [Related]  

  • 58. Escalating MS drug costs in the US: Puzzling, troubling, and suspicious.
    Murray TJ; Brown MG
    Neurology; 2015 May; 84(21):2105-6. PubMed ID: 25911109
    [No Abstract]   [Full Text] [Related]  

  • 59. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Rittenhouse BE
    Neurology; 2015 Nov; 85(19):1727-8. PubMed ID: 26866071
    [No Abstract]   [Full Text] [Related]  

  • 60. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Tischner JR
    Neurology; 2015 Nov; 85(19):1727. PubMed ID: 26553943
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.